Long-term survival analysis of AML1/ETO positive leukemia patients with expression of CD56 and CD64
MENG Wei
LIANG Meng-ni
WEI Yong-qiang
YU Guo-pan
YIN Chang-xin
JIANG Ling
Abstract：Objective To investigate the effects of CD56 and CD64 on long - term survival in patients with AML/ETO - positive acute myeloid leukemia. Methods An institutional retrospective study was performed on 35 AML/ ETO -positive acute myeloid leukemia patients from May 2010 to August 2016. Univariate and multifactorial analysis of potential factors influencing survival,including gender,age,initial WBC count,immunophenotype,chemotherapy course to com-plete remission (CR),c - kit gene mutation,complex karyotype and extramedullary leukemia,were carried out by using Log - rank test and Cox regression model. Results Thirty - five patients were followed up for 3 to 87 months (median 33 months). Univariate analysis showed that age,sex,extramedullary leukemia,complex karyotype,chemotherapy course to CR,CD19 or CD9 didn′t significanlty affect long - term survival,while initial WBC count,CD56 and CD64 were critical factors on it (P = 0. 045,P = 0. 044,P = 0. 045). Multivariate analysis showed that CD56 expression was an independent prognostic factor for AML/ ETO positive patients with acute myeloid leukemia. Patients with both CD56 positive and CD64 positive got the least long - term survival rate (P = 0. 012). Conclusion CD56 is an independent prognostic factor for AML/ ETO - positive acute myeloid leukemia patients,and CD56 and CD64 double - expression have the poorest prognosis.
Keywords：CD56CD64AML1 / ETO +extramedullary leukemia
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 2773-2777 )